News

News 04.11.2025 INGELHEIM, Germany and ZURICH, Switzerland--(BUSINESS WIRE)--Boehringer Ingelheim and CDR-Life, Inc. today announced a new global licensing agreement to develop CDR-Life’s unique antibody-based molecule CDR111 for autoimmune diseases. CDR111 is a trispecific M-gager®, an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset. “Our...

News 31.10.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate...

News 29.10.2025 Together with ETH Zürich and the University Children’s Hospital Zürich, InSphero developed and characterized a gravity-driven microfluidic platform that enables continuous co-culture of suspension cells with 3D microtissues under physiologically relevant flow. No pumps, no tubing, just smart design. The study presents the design and characterization of the system, the scientific...

News 27.10.2025 ZURICH, Switzerland--(BUSINESS WIRE)--CDR-Life, Inc., a biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced the first clinical data showing that CDR404, the company’s lead M-gager® TCE, achieved all four canonical pharmacodynamic (PD) hallmarks of TCE activity in patients with MAGE-A4+ solid tumors. The...

News 23.10.2025 Schlieren, Switzerland and Washington, D.C. — The Schlieren-based biotech company InSphero is presenting the HUMAIN Award for the second time this year, in collaboration with the Physicians Committee for Responsible Medicine. The five winning teams are from Switzerland, Portugal, the United States, Spain, and Germany. According to a press release, InSphero...